Compare Amylx Pharmaceuticals Inc (AMLX) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hasbro, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.17 (market cap $1.98B), while Hasbro, Inc. trades at $80.36 (market cap $11.17B). The key difference: Hasbro, Inc. is far larger — about 5.6× Amylx Pharmaceuticals Inc's market cap, and Hasbro, Inc. pays a 3.55% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HAS | |
|---|---|---|
Market Cap | $1.98B | $11.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $105.88 |
52-Week Low | $7.64 | $70.95 |
Enterprise Value | $1.70B | $13.44B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Hasbro (HAS) trades at $78.96, up 2.03% today, with a bearish technical signal but bullish oscillators suggesting potential reversal. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B. Recent earnings beats and a $0.70 dividend highlight operational resilience, while analyst consensus targets $104.80. News highlights include new product launches like Blooms by Play-Doh and strong performance in the Wizards segment.
Outlook: Upside exists from analyst targets and earnings momentum, but risks include high debt, margin pressure, and competitive threats. The stock presents a contrarian opportunity if operational improvements continue, though volatility near key support at $76 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
